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Mini abstract 
In this study we report that self-perception of fracture risk captures some aspect of fracture 
risk not currently measured using conventional fracture prediction tools and is associated 
with improved medication uptake. It suggests that adequate appreciation of fracture risk may 
be beneficial and lead to greater healthcare engagement and treatment. 
Abstract 
Purpose: This study aimed to assess how well self-perception of fracture risk, and fracture 
risk as estimated by the fracture prediction tool FRAX, related to fracture incidence and 
uptake and persistence of anti-osteoporosis medication among women participating in the 
Global Longitudinal study of Osteoporosis in Women (GLOW).  
Methods: GLOW is an international cohort study involving 723 physician practices across 10 
countries in Europe, North America and Australia. 60393 women aged ≥55 years completed 
baseline questionnaires detailing medical history, including co-morbidities, fractures and self-
perceived fracture risk (SPR). Annual follow-up included self-reported incident fractures and 
anti-osteoporosis medication (AOM) use. We calculated FRAX risk without bone mineral 
density measurement. 
Results: Of the 39241 women with at least one year of follow-up data, 2132 (5.4%) sustained 
an incident major osteoporotic fracture over 5 years of follow-up. Within each SPR category, 
risk of fracture increased as the FRAX categorisation of risk increased. In GLOW only 11% 
of women with a lower baseline SPR were taking AOM at baseline, compared with 46% of 
women with a higher SPR. AOM use tended to increase in the years after a reported fracture. 
However, women with lower SPR who fractured still reported lower AOM rates than women 
with or without a fracture but a higher SPR.  
Conclusions: These results suggest that SPR captures some aspect of fracture risk not 
currently measured using conventional fracture prediction tools and is also associated with 
improved medication uptake. 
 
 
 
Keywords: Fracture risk, FRAX, Osteoporosis, Treatment, Adherence 
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Introduction 
Osteoporosis-related fractures confer a significant healthcare burden. Approximately one in 
two women and one in four men over age 50 will have an osteoporosis-related fracture in 
their lifetime [1].  In addition to the personal impact on millions of people around the world, 
fractures caused by osteoporosis represent a major and growing socioeconomic burden.  In 
2005 in the United States alone, there were 297,000 hip fractures, 547,000 vertebral fractures, 
397,000 wrist fractures, 135,000 pelvic fractures, and 675,000 fractures at other sites costing 
nearly $17 billion [2]. The cost of osteoporotic fracture in the UK approaches £3 billion 
annually and, across the EU, the estimated total economic cost of the approximately 3.5 
million fragility fractures in 2010 was €37 billion [3]. As the population ages, costs are 
expected to escalate. 
Therapeutic options can significantly reduce the risk of osteoporosis-related fractures. 
However, suboptimal use of anti–osteoporosis medications (AOM) and low adherence among 
women who have started AOM are recognised problems, similar to adherence problems 
reported for many non-communicable diseases such as ischaemic heart disease, chronic 
obstructive pulmonary disease and osteoporosis [4-6]. More than one third of people do not 
comply with prescribed treatment regimens [7]. A more recent study of patients, who 
received AOM within 1 year after fracture, reported that persistence with AOM was 75%  
and 45.3% after 1 and 5 years respectively  [8]. 
It is possible that empowering patients through improved understanding of their disease and 
adequate appreciation of fracture risk may be beneficial, as increased self-awareness might 
lead to greater healthcare engagement and treatment.  Although, it has been demonstrated that 
a person’s perception of osteoporosis is associated with improved medication adherence [9], 
it has been reported that people with an increased fracture risk commonly underestimate their 
actual risk, suggesting that there might be a disconnect between self-perception of fracture 
risk and actual fracture risk [10]. 
In a study to consider self-perception of fracture risk further, we aimed to determine how well 
a person’s fracture risk perception aligned with fracture probability as assessed by FRAX in a 
large, multinational cohort study, and also assess whether incident fracture was associated 
with altered (i) use of AOM (ii) self-reported adherence to AOM. 
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Methods 
Study design 
GLOW is an observational cohort study conducted in physicians’ practices at 17 sites in 10 
countries (Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, UK and 
USA). Details of the study design have been previously described [11]. In brief, typical 
practices of each region were recruited through primary care networks. Each practice 
provided a list of women aged 55 years or older, who within the past 24 months had 
consulted their primary care physician.  Sampling was age-stratified to ensure that two thirds 
of women were 65 years of age or older, excluding those who were unable to complete the 
study survey due to cognitive impairment, language barriers, institutionalisation or illness.  
Each study site obtained ethics committee approval to conduct the study in the specific 
location.  
 
Questionnaires   
Self-administered questionnaires covered domains that included: demographic characteristics 
and risk factors, perception about fracture risk relative to women of the same age (ranked as 
much lower’, ‘little lower’, ‘about the same’, ‘little higher’ and ‘much higher’, on a 5 point 
scale), medication use, medical diagnosis, healthcare use and access, physical activity and 
physical and emotional health status including self - rated health. Self-reports of personal risk 
factors included: current weight and height, parental hip fracture, falls in the past 12 months, 
current use of cortisone or prednisolone, diagnosis of rheumatoid arthritis, personal history of 
fracture (clavicle, arm, wrist, spine, rib, hip, pelvis, upper leg, lower leg, and ankle) since age 
45 years, current cigarette smoking and consumption of three or more units of alcohol daily.. 
Follow up questionnaires were sent annually for 5 years. These asked about any incident 
fractures and requested information about site of fracture and any hospital treatment received. 
FRAX  
FRAX scores were calculated for women from responses on their baseline survey, without 
inclusion of bone mineral density measurement. The FRAX tool with or without the use of 
BMD is a well-validated instrument and enhances fracture risk prediction [12]. Women were 
classified as ‘high risk’, ‘medium risk’ and ‘low risk’ if their FRAX 10 year probability of 
 6 
 
major osteoporotic fracture and hip fracture was both ≥20% and ≥3%, either ≥20% or ≥3%, 
or both ≤20% and ≥3% respectively. 
Medication 
Women were considered to be taking anti-osteoporosis medications (AOM) if they reported 
current use of alendronate, etidronate, ibandronate, risedronate, pamidronate, zoledronate, 
strontium ranelate, calcitonin, PTH [1-84], teriparatide, raloxifene, or tibolone.  
Analysis 
Data from women who completed a baseline questionnaire and at least one year of follow-up 
were included in the analysis. Women who reported any incident major fracture (hip, spine, 
upper arm, shoulder, or wrist) that occurred between baseline and their last year of 
consecutive follow-up-- between 1 and 5 years after baseline-- were classified as incident 
fracture positive. If a woman reported more than one incident fracture, the date of her earliest 
fracture was used. For this analysis SPR was defined as ‘higher’ when women rated their 
SPR, using a five point scale as ‘little higher’ and ‘much higher’; and as ‘lower’ when rated 
as ‘much lower’ or ‘little lower’, compared with women of the same age. A Cox proportional 
hazards model predicting 5-year incident fracture based on SPR category, FRAX risk 
category, and an interaction term of SPR with FRAX was used to calculate unadjusted hazard 
ratios (HRs) and 95% confidence intervals (CI) for each SPR and FRAX risk category 
combination. A separate Cox proportional hazards model predicting 5-year incident fracture 
based on SPR and FRAX was used to determine if the two were independently significant 
predictors of fracture.  Finally, as a sensitivity analysis, two additional Cox proportional 
hazards model predicting 5-year incident fracture were run. The first added number of falls 
reported in the past 12 months on the baseline GLOW survey to a model with SPR and 
FRAX, and was used to determine if the relationship between SPR, FRAX, and incident 
fracture would remain after adjusting for history of falls.  The second added a variable for the 
country of the GLOW respondent to a model with SPR and FRAX, to determine if the 
relationship between SPR, FRAX, and incident fracture would remain after adjusting for 
geographic region. Associations were considered significant if the p-value was <0.05. All 
calculations were done using SAS version 9.4. 
 
Results 
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A total of 60,393 patients from 723 physicians’ practices enrolled in the study between 
October 2006 and February 2008.  Approximately 25000 participants were recruited in 
Europe, 28000 in USA, and almost 7000 in Canada and Australia. There were 39,241 (65%) 
women with at least one year of follow-up data.  The mean age was 68 years and mean 
weight 70kg. History of maternal hip fracture was reported by 14% participants and personal 
history of a fracture of the wrist, spine, or hip was 11% at baseline. The reported prevalence 
of common comorbid conditions was: 11% asthma, 0.8% rheumatoid arthritis, 50% 
hypercholesterolaemia and 49% hypertension; 19% of women said their health status was 
“fair” or “poor”. Fifty six percent of women expressed “some” concern about osteoporosis 
and 21% said they were “very concerned” about the condition. When women rated their SPR 
(their own risk of fracture compared with women their own age), 36% rated their risk as 
lower and 17% as higher.  The remaining 46% considered their risk “the same.” Women who 
rated their SPR as higher also reported more falls than women who rated their SPR as lower; 
among women with lower SPR only 11% reported two or more falls in the prior year, 
compared to 23% of women with higher SPR (p<0.0001). The number of reported 
comorbidities was also significantly associated with SPR (p<0.0001). Similar to falls, women 
who rated their SPR higher reported more comorbidities than women rating their SPR as 
lower with figures of 20% and 17% for 3 comorbidities, 11% and  6.6% for 4 comorbidities, 
and 7.5% and 3.1% for  ≥ 5 comorbidities respectively. 
Incident major fracture (hip, wrist, spine, shoulder, arm) was reported by 2132 (5.4%) women 
over 5-years of follow-up. Table 1 shows the associations between SPR and FRAX-derived 
fracture risk. Within each SPR category, risk of incident fracture increased as FRAX 
categorisation of risk increased. The highest risk of fracture was seen in women with both a 
high SPR and high FRAX risk.  In a Cox model containing both FRAX risk and SPR both 
variables were highly significant (p<0.0001), suggesting that a woman’s own perception of 
fracture risk is an additional predictor of fracture beyond that calculated by FRAX. In the 
model, compared to women with lower SPR, women with SPR of “about the same” as other 
women their age had a slightly increased fracture hazard ratio (95% CI) of 1.15 (1.04 – 1.27). 
Women with SPR “much or a little higher” as other women their age had almost twice the 
rate of fracture, with a hazard ratio (95% CI) of 1.88 (1.68 – 2.11).  In the same model, 
compared to women with low FRAX risk, women with medium FRAX risk had a fracture 
hazard ratio (95% CI) of 1.53 (1.37 – 1.70), and women with high FRAX risk had a fracture 
hazard ratio (95% CI) of 2.81 (2.52 – 3.12). FRAX was a stronger predictor of a fracture than 
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SPR (Type 3 Wald chi-square values of 366.34 and 134.40 respectively) but both variables 
had a highly significant, independent association with fracture. 
Woman who have fallen consider themselves at higher risk for fracture (p < 0.0001).  It is 
possible that women reporting a high SPR may do so because they perceive their risk of falls 
to be higher than women of the same age. We attempted to investigate this issue In a separate 
Cox model that included SPR, FRAX, and the number of falls in the year prior to the 
survey’s baseline, the falls variable was a significant predictor of a subsequent fracture with a 
hazard ratio (95% CI) of 1.24 (1.12-1.37) for one fall and 1.66 (1.48-1.85) for ≥ 2 falls, but 
the results for SPR and FRAX both remained highly significant. Moreover, the Type 3 Wald 
chi-square values for SPR (107.13) and FRAX (345.58) were higher than that of the falls 
variable (81.68) and the HRs for SPR and FRAX did not change appreciably. This indicates 
that both have a significant, independent contribution towards predicting fracture, but that 
SPR was stronger.  
At baseline, 7579 (20%) of the cohort reported taking an AOM. There were 565 incident 
fractures reported at year 1, 531 at year 2, 494 at year 3, and 534 at year 5. Of 14238 women 
in GLOW with a lower baseline SPR, 1527 (11%) were taking an AOM at baseline, while of 
6829 women with a higher SPR 3042 (46%) were taking an AOM at baseline. AOM use 
tended to increase in the year following an incident fracture in women with lower or higher 
SPR. For example, among women with a lower baseline SPR 11% were taking AOM at 
baseline and 23% at year 1 if the woman reported an incident fracture, while the 
corresponding figures for those with higher baseline SPR were 46% and 55% respectively. 
However, among women with lower SPR who reported an incident fracture, use of AOM was 
consistently lower than that of women with higher SPR regardless of their fracture status 
(p<0.0001) (Figure 1).  
Results presented throughout did not include country of origin. Although we repeated 
analyses and  in  a Cox model that included SPR, FRAX, and the country of the GLOW 
survey respondent, the country variable was  significant (p<0.0001), but again without 
substantial change in effect size or direction. 
 
 
Discussion 
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We have demonstrated that SPR of fracture does capture some aspect of fracture risk not 
currently measured using the conventional fracture prediction tool FRAX, and also translates 
to improved medication uptake.Self-perception of risk of a condition is a difficult concept, as 
it requires an individual to compare their own health status to others. In previous work, SPR 
of osteoporosis and osteoporotic fractures has previously been reported to be underestimated 
in postmenopausal women worldwide. Rothmann et al, observed that women participating in 
the Risk-Stratified Osteoporosis Strategy Evaluation (ROSE) study underestimated their 
fracture risk compared to the risk estimated by FRAX, although it demonstrated that women 
did have some understanding of the importance of some risk factors such as prior fracture, 
parental history and falls [13]. Women at increased fracture risk generally perceive their risk 
to be lower or about the same as women of the same age, as has been shown previously in 
GLOW [10, 14]. Our data suggest that SPR offers a further contribution to fracture 
prediction, independent of fracture prediction by FRAX.  
An increased number of falls present in women with higher SPR in this study; a variable not 
captured by FRAX, is a possible partial explanation for the independent addition of SPR to 
fracture prediction algorithms. Falls increase fracture risk among older adults and multiple 
falls are a marker of physical frailty. However, even in our model including falls, SPR 
remained a significant independent predictor of fracture. Interestingly, fear of falling, a self-
perceived concept, has been found to be predictive of future falls [15]. Polypharmacy may be 
another explanation for our findings. Due to the age range of our study group, most 
individuals suffered from at least one chronic condition. Some comorbidities increase falls 
risk, which could lead to increased fracture risk; for example neurological diseases have been 
shown to have the highest fracture rates among participants of the GLOW study [14]. In this 
study higher number of comorbidities was associated with higher SPR. The presence of 
chronic disease may imply a need to take prescribed drugs that might increase the risk of 
falling. Several types of drugs are associated with a significant risk of falls. Use of 
antidepressants has been reported to have the strongest association with falls, but also other 
classes of medication among other including antihypertensives, nonsteroidal anti-
inflammatory drugs and antipsychotics were found to have positive association with falling 
[16]. Furthermore, drug adherence may be lower in frail patients with cognitive impairment.  
SPR was also associated with self-reported AOM uptake. In this large, international 
observational study women with higher SPR were more likely to report AOM use than 
women with lower SPR. AOM use was higher in the year after an incident fracture for 
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women in both groups with lower or higher SPR, but the absolute rate of AOM use was 
always higher among women with higher SPR. Whether changing the SPR from lower to 
higher would lead to improve in uptake or adherence to AOM requires further investigation. 
It is well documented that prescription rates of AOM following osteoporotic fracture are low 
and adherence to medication is poor.  Previous studies suggest that just 17% of treatment 
naive women with a new fracture began AOM in the first year of follow-up and between 26 - 
70% of women prescribed oral bisphosphonates continued to take them at 1 year [8, 17]. This 
is consistent with our findings, in which a high proportion of women with incident fracture 
did not start AOM.  
Established predictors of treatment initiation include a diagnosis of osteoporosis and low 
measured bone density [17].  In the current study, SPR of fracture also predicted osteoporosis 
treatment. Other studies also found that patient health beliefs predicted treatment. For 
example, patient beliefs in the benefits of medications, and distrust of medications were 
reported to differentiate between initiators and non-initiators of osteoporosis medication [18, 
19].  It is well recognised that a well-informed, empowered patient should be at the heart of 
the chronic disease management model. In cases of osteoporosis, it may be that improved 
understanding of the disease, its management and appreciation of fracture risk among patients 
would help to tackle under-use of AOM, and we hope to address this in future work, in a 
randomised controlled trial setting.  
 Our study has some limitations. Educational and cultural differences may influence SPR of 
fracture. While we performed a sensitivity analysis for country, in this cohort data regarding 
ethnicity were not available apart from in women from USA and Canada. Furthermore, 
although some educational data were collected, it is difficult to draw conclusions due to 
difference in the educational systems between the participating countries.  Finally, 
information on AOM use was based upon self-reported questionnaire and not verified by 
pharmacy records. It has been reported, however, that agreement between self-report and 
pharmacy data is high [20]. 
In conclusion, our data suggest that self-reported risk of fracture does capture an aspect of 
fracture risk not currently measured using the conventional fracture predictions tool FRAX, 
and that greater self-reported risk also translates to improved osteoporosis medication uptake. 
These observations suggest that education interventions may help to improve medication 
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uptake and adherence, and that a woman’s perception of her own risk of fragility fracture 
should be considered when counselling her regarding management of osteoporosis. 
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